Prognosis and tumor-infiltrating lymphocytes (TILs) in estrogen receptor (ER)-low metastatic breast cancer (MBC): Analysis from a large multi-institutional cohort and the TONIC phase II trial with nivolumab.Federica Miglietta, Maria Vittoria Dieci, Fabio Secomandi et al.|Journal of Clinical Oncology|2024Cited by 1
Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC TrialFederica Miglietta, Maria Vittoria Dieci, Manon de Graaf et al.|Clinical Cancer Research|2025Cited by 1
Supplementary Table S3 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC TrialFederica Miglietta, Maria Vittoria Dieci, Manon de Graaf et al.|Unknown|2025Cited by 0
Supplementary Table S4 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC TrialFederica Miglietta, Maria Vittoria Dieci, Manon de Graaf et al.|Unknown|2025Cited by 0
Supplementary Table S1 from Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC TrialFederica Miglietta, Maria Vittoria Dieci, Manon de Graaf et al.|Unknown|2025Cited by 0